Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNA2 | P20248 | 1/20 | 0.49 |
| ▸ | CDK2 | P24941 | 1/20 | 0.49 |
| ▸ | SYK | P43405 | 6/20 | 0.47 |
| ▸ | CTSC | P53634 | 1/20 | 0.45 |
| ▸ | WEE1 | P30291 | 2/20 | 0.44 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.44 |
| ▸ | BTK | Q06187 | 4/20 | 0.44 |
| ▸ | CDK4 | P11802 | 3/20 | 0.42 |
| ▸ | CCND1 | P24385 | 2/20 | 0.42 |
| ▸ | CDK6 | Q00534 | 1/20 | 0.42 |
| ▸ | WNT3A | P56704 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL610952 | 0.89 | WEE1 (0.51) | CCNA2CDK2WEE1BTKCDK4 | |
| SCHEMBL608637 | 0.85 | SYK (0.47) | CDK2SYKWEE1BTKCDK4 | |
| SCHEMBL10256584 | 0.85 | CCND3 (0.48) | CCNA2CDK2CDK4CCND1CDK6 | |
| SCHEMBL1394803 | 0.84 | WEE1 (0.41) | CCNA2CDK2SYKCTSCWEE1 | |
| Hydrochloric Acid SCHEMBL1393269 | 0.84 | CDK2 (0.47) | CCNA2CDK2CDK4CCND1CDK6 | |
| SCHEMBL610905 | 0.83 | SYK (0.43) | CCNA2CDK2SYKWEE1BTK | |
| SCHEMBL1393440 | 0.82 | BTK (0.46) | CCNA2CDK2WEE1BTKCDK4 | |
| SCHEMBL610280 | 0.82 | CDK6 (0.41) | CCNA2CDK2SYKBTKCDK4 | |
| SCHEMBL10256308 | 0.80 | WNT3A (0.48) | CCNA2CDK2BTKCDK4CCND1 | |
| SCHEMBL25959458 | 0.79 | BTK (0.49) | CCNA2CDK2SYKBTKCDK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8940741-B2 | Inhibitors of bruton's tyrosine kinase | HOFFMANN-LA ROCHE INC. (US) | 2015-01-27 | — | — | US | disclosed |
| US-8940741-B2 | Inhibitors of bruton's tyrosine kinase | HOFFMANN-LA ROCHE INC. (US) | 2015-01-27 | — | — | US | disclosed |
| US-8940741-B2 | Inhibitors of bruton's tyrosine kinase | HOFFMANN-LA ROCHE INC. (US) | 2015-01-27 | — | — | US | disclosed |
| EP-2603500-B1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | HOFFMANN LA ROCHE (CH) | 2014-11-19 | — | — | EP | disclosed |
| EP-2603500-B1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | HOFFMANN LA ROCHE (CH) | 2014-11-19 | — | — | EP | disclosed |
| US-20130178461-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | HOFFMANN-LA ROCHE INC. (US) | 2013-07-11 | — | — | US | disclosed |
| US-20130178461-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | HOFFMANN-LA ROCHE INC. (US) | 2013-07-11 | — | — | US | disclosed |
| US-20130178461-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | HOFFMANN-LA ROCHE INC. (US) | 2013-07-11 | — | — | US | disclosed |
| US-8481540-B2 | Inhibitors of bruton's tyrosine kinase | HOFFMANN-LA ROCHE INC. (US) | 2013-07-09 | — | — | US | disclosed |
| US-8481540-B2 | Inhibitors of bruton's tyrosine kinase | HOFFMANN-LA ROCHE INC. (US) | 2013-07-09 | — | — | US | disclosed |
| US-8481540-B2 | Inhibitors of bruton's tyrosine kinase | HOFFMANN-LA ROCHE INC. (US) | 2013-07-09 | — | — | US | disclosed |
| EP-2603500-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | F.HOFFMANN-LA ROCHE AG (CH) | 2013-06-19 | — | — | EP | disclosed |
| WO-2012020008-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | F. HOFFMANN-LA ROCHE AG (CH) | 2012-02-16 | — | — | WO | disclosed |
| WO-2012020008-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | F. HOFFMANN-LA ROCHE AG (CH) | 2012-02-16 | — | — | WO | disclosed |
| US-20120040949-A1 | Inhibitors of Bruton's Tyrosine Kinase | BERTHEL STEVEN JOSEPH (US) | 2012-02-16 | — | — | US | disclosed |
| US-20120040949-A1 | Inhibitors of Bruton's Tyrosine Kinase | BERTHEL STEVEN JOSEPH (US) | 2012-02-16 | — | — | US | disclosed |
| US-20120040949-A1 | Inhibitors of Bruton's Tyrosine Kinase | BERTHEL STEVEN JOSEPH (US) | 2012-02-16 | — | — | US | disclosed |
| US-20110301145-A1 | PYRIDAZINONES, METHOD OF MAKING, AND METHOD OF USE THEREOF | Gilead Connecticut INc. (US) | 2011-12-08 | — | — | US | disclosed |
| US-20110301145-A1 | PYRIDAZINONES, METHOD OF MAKING, AND METHOD OF USE THEREOF | Gilead Connecticut INc. (US) | 2011-12-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110301145-A1 | PYRIDAZINONES, METHOD OF MAKING, AND METHOD OF USE THEREOF | BTK, SYK, LCK | CCNA2 1346/4885CDK2 396/4885SYK 2/4885 |
| US-20120040949-A1 | Inhibitors of Bruton's Tyrosine Kinase | BTK, SYK, LYN | CCNA2 833/4885CDK2 239/4885SYK 2/4885 |
| US-20130178461-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | BTK, SYK, LYN | CCNA2 833/4885CDK2 239/4885SYK 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.